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Background
BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) are members 
of the tumor necrosis factor family and promote B cell survival and proliferation. We 
evaluated the correlation between serum concentration of BAFF or APRIL and severity 
of acute graft-versus-host disease (GVHD).
Methods
Fifteen patients who received allogeneic hematopoietic stem transplantation for leukemia 
and developed acute GVHD were enrolled. We determined serum concentrations of BAFF 
and APRIL at the onset of the first clinical manifestation of GVHD by enzyme-linked 
immunosorbent assay. 
Results
Nine patients had grade 2 acute GVHD, and 6 had grade 3-4 acute GVHD. The BAFF serum 
concentration was higher in patients with grade 3-4 acute GVHD (1,093.42 in grade 2 
vs. 2,171.99 pg/mL in grade 3-4), although the difference was not significant (P=0.077). 
However, the ratio of BAFF serum concentration to absolute lymphocyte count (ALC) 
(BAFF/ALC) was significantly higher in patients with grade 3-4 acute GVHD (P=0.045). 
The APRIL serum concentration and APRIL/ALC ratio showed similar results (P=0.077 
and P=0.013, respectively).
Conclusion
Patients with grade 3-4 acute GVHD had higher BAFF/ALC and APRIL/ALC ratios than 
patients with grade 2 acute GVHD. These findings suggest that B cells might play an 
important role in the development of acute GVHD, and that the BAFF and APRIL 
concentrations in serum might be significant predictive factors for estimating the severity 
of acute GVHD. Their clinical significance should be further evaluated in a larger patient 
population.
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INTRODUCTION
Graft-versus-host disease (GVHD) is a significant cause 
of morbidity and mortality after allogeneic hematopoietic 
stem cell transplantation (HSCT), and is a major barrier against 
successful allogeneic HSCT [1]. GVHD is a complex disease 
resulting from an exaggerated immune response of the donor’s 
CD4
＋ and CD8
＋ T cells against the recipient’s tissue. In 
acute GVHD, the subsequent proliferation and differentiation 
of these activated T cells stimulates additional effectors that 
mediate tissue damage, including cytotoxic T cells, natural 
killer (NK) cells, tumor necrosis factor (TNF)-α, and IL-1. 
Although the pathophysiology of chronic GVHD remains 
poorly understood, T cells have been identified as key players 
in both acute and chronic GVHDs, and most established Korean J Hematol 2011;46:175-9.
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drugs for GVHD have been developed to target T cells [2]. 
However, few effective therapies are currently available for 
the treatment of GVHD, and the currently used immuno-
suppressive agents are mostly nonspecific and, unfortunately, 
are associated with severe adverse effects, including serious 
infections [2]. Therefore, a better understanding of the basic 
mechanisms underlying the development of GVHD is 
urgently needed. 
Recently, several studies have demonstrated that B cells 
are also involved in the immunopathophysiology of acute 
and chronic GVHDs [3-5]. Early-phase clinical trials indicate 
that B cell depletion with rituximab has beneficial effects 
on both acute and chronic GVHDs [3].
BAFF (B cell-activating factor) and APRIL (a proliferation- 
inducing ligand) are members of the TNF family that act 
as B cell trophic factors, promoting the survival and 
proliferation of B cells [6]. Both BAFF and APRIL and their 
receptors are strongly up-regulated in many autoimmune 
disorders [3, 6, 7]. Because the clinical features of GVHD 
are similar to those of autoimmune diseases, the elevated 
serum concentrations of BAFF and APRIL seen in GVHD 
may be closely related to the processes underlying its 
development. Several evidences clearly demonstrate that B 
cells are involved in the pathogenesis of chronic GVHD. 
Furthermore, the highest BAFF concentrations were found 
in the sera of patients with chronic GVHD, and these were 
significantly higher than in patients with inactive disease 
or in patients who never developed chronic GVHD after 
allogeneic HSCT [8, 9]. A recent study suggested that high 
BAFF concentration during the peri-transplantation period 
may be predictive of acute GVHD [10]. However, whether 
B cells are involved in acute GVHD is still controversial. 
Higher grades of acute GVHD are often unresponsive to 
high doses of steroid therapy and, as a result, frequently 
have fatal outcomes [1, 2]. Therefore, early diagnosis and 
prediction of the severity of acute GVHD may be very 
important. However, acute GVHD is frequently diagnosed 
only by close examination of skin lesions or monitoring 
of clinical signs such as diarrhea, and only a few biochemical 
tests are available to accurately diagnose and predict the 
severity of GVHD [11]. 
There have been only a few reports regarding the 
relationship between elevated serum BAFF and the develop-
ment of acute GVHD. In this study, we assessed the value 
of serum BAFF and APRIL measurements taken at diagnosis 
of acute GVHD in estimating the severity of the condition.
MATERIALS AND METHODS
1. Patients and samples
Fifteen patients who received allogeneic HSCT for 
leukemia and developed acute GVHD were enrolled in this 
study. All patients received GVHD prophylaxis with a 
calcineurin inhibitor (cyclosporine or tacrolimus) with or 
without a short course of methotrexate (MTX), and none 
of the grafts were depleted of T cells. Acute GVHD was 
graded based on the revised system developed by the 
International Bone Marrow Transplant Registry (IBMTR) 
in 1997 [12]. In the absence of histologic or clinical signs 
or symptoms of chronic GVHD, the persistence, recurrence, 
or new onset of characteristic skin, gastrointestinal tract, 
or liver abnormalities were classified as acute GVHD 
regardless of the time after transplantation.
All blood samples were collected at the onset of the first 
clinical manifestation of GVHD and diagnosis of acute 
GVHD. Serum was separated from whole blood cells via 
10 minutes of centrifugation at 2,500 rpm. The serum samples 
were stored at -80°C until tested for levels of BAFF and 
APRIL.
2. Enzyme-linked immunosorbent assays 
Commercially available enzyme-linked immunosorbent 
assays (ELISAs) were used to measure the concentrations of 
BAFF and APRIL.　The concentration of serum BAFF was 
measured using the frozen serum samples after thawing. 
Fifty microliters of each serum was added to each well of 
an ELISA plate that was coated with a mouse monoclonal 
antibody against human BAFF (R&D Systems, Minneapolis, 
MN, USA), according to the manufacturer’s recommenda-
tions. After incubation at room temperature for 2 hrs, samples 
were aspirated and the plates were washed. The plates were 
then incubated for 2 hrs with an antibody against BAFF 
conjugated to horseradish peroxidase (HRP). Tetramethyl-
benzidine (TMB) was used as a substrate, and optical density 
was read at 450 nm. The serum concentration of BAFF 
(pg/mL) was calculated based on the standard curve produced 
with 40,000 pg/mL of recombinant human BAFF. The 
minimal detectable concentration of BAFF was 1.5 pg/mL. 
Each sample was tested in duplicate, and the average value 
was reported.
S e r u m  l e v e l s  o f  A P R I L  w e r e  a l s o  m e a s u r e d  b y  E L I S A  
(Human APRIL ELISA BMS2008; Bender MedSystems 
GmbH, Vienna, Austria). APRIL ELISA was performed 
according to the manufacturer’s instructions. The color 
reaction and absorbance readings were performed in the 
same manner as for the BAFF ELISA. The serum con-
centration of APRIL (ng/mL) was calculated based on a 
standard curve from 50 ng/mL to 0 ng/mL, and the minimal 
detectable concentration of APRIL was 0.4 ng/mL. All 
samples were analyzed in duplicate, and the average value 
was reported.
3. Statistical analysis
The relationships between serum BAFF and APRIL levels 
and continuous clinical variables were evaluated using 
Spearman’s correlation test. Mann-Whitney U-test was used 
to evaluate the relationship of serum BAFF and APRIL levels 
with severity of acute GVHD. All statistical analyses were 
conducted using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) 
and a 2-sided P-value of less than 0.05 was considered 
statistically significant.Korean J Hematol 2011;46:175-9.
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Table 2. Serum BAFF and APRIL levels and acute GVHD characteristics. 
UPN Disease Sex Age
Onset date of 
acute GVHD
a)
Grade of acute 
GVHD
ALC
b)
(×10
9/L)
Serum BAFF
b)
(pg/mL)
Serum APRIL
b)
(ng/mL)
  1 AML M 18 15 3 1.05 687.17 2.15
  2 CML F 18 12 2 0.56 973.70 7.09
  3 ALL M 36 12 2 0.77 372.92 0.81
  4 AML F 45 24 4 1.10 3,678.67 3.23
  5 AML F 50 224 2 1.58 546.80 0.80
  6 AML M 51 197 2 1.45 2,455.64 0.70
  7 CML M 35 45 2 0.86 666.05 1.07
  8 ALL M 29 60 2 1.35 669.33 1.80
  9 AML M 29 240 2 0.92 895.04 1.31
10 AML M 51 110 3 0.48 762.33 1.17
11 AML M 29 91 3 0.83 2,781.95 1.36
12 AML M 20 15 3 0.84 1,207.33 3.60
13 AML F 20 13 2 0.90 966.43 1.24
14 ALL M 38 18 2 3.07 2,294.87 1.55
15 AML F 45 14 4 1.23 3,914.48 4.39
a)Onset date of acute GVHD after allogeneic HSCT, 
b)Laboratory results at the diagnosis of acute GVHD.
Abbreviations: AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; M, male; F, 
female; GVHD, graft-versus-host disease; ALC, Absolute lymphocyte count; BAFF, B cell-activating factor; APRIL, a proliferation-inducing ligand.
Table 1. Patient characteristics.
N
Age (years, median, range) 35 (18-51)
Male : Female 10 : 5
Underlying disease
  AML/ALL 10/3
  CML 2
Stem cell source,    4/11
 bone marrow/peripheral blood
Donor type, sibling/unrelated   6/9
HLA, match/mismatch 14/1
Conditioning regimen,  13/2
 myeloablative/nonmyeloablative
Conditioning regimen,    4/11
 TBI based/non-TBI based
Infused total nuclear cells  15.02 (7.50-31.41)
 (×10
8/kg, median, range)
Infused CD34
＋ cells    8.01 (1.64-17.24)
 (×10
6/kg, median, range)
Abbreviations: AML, acute myelogenous leukemia; ALL, acute 
lymphoblastic leukemia; CML, chronic myelogenous leukemia; 
TBI, total body irradiation.
RESULTS
1. Patient characteristics
Clinical characteristics of the 15 enrolled patients are 
described in Table 1. The median patient age was 35 years 
(range, 18-51 years). This study included 9 patients with 
acute myelogenous leukemia (AML), 4 with acute lympho-
blastic leukemia (ALL), and 2 with chronic myelogenous 
leukemia (CML). Fourteen patients received HLA-identical 
allogeneic HSCT (6 related and 8 unrelated) and 1 patient 
received HLA-mismatched unrelated allogeneic HSCT. All 
patients received non-T cell-depleted grafts. A myeloablative 
conditioning regimen was used in all but 2 cases. Total body 
irradiation (TBI) was used as the conditioning regimen for 
4 patients (1,320 cGy of TBI and cyclophosphamide).
Ten patients received cyclosporine-based GVHD pro-
phylaxis (3 mg/kg/day adjusted for blood levels between 200 
and 400 ng/mL): 4 received cyclosporine alone and 6 received 
cyclosporine and a short course of MTX. MTX was 
a d m i n i s t e r e d  a t  a  d o s a g e  o f  1 0  m g / m
2 on days ＋1,  ＋3, 
＋6, and ＋11. Tacrolimus-based prophylaxis was admini-
stered to 5 patients who received unrelated HSCT: 4 received 
tacrolimus alone and 1 received tacrolimus and a short course 
of MTX. Tacrolimus was administered intravenously as a 
continuous infusion at a dose of 0.03 mg/kg from days −1 
to ＋21, and then orally at a total dose of 0.12 mg/kg/day, 
divided into 2 doses, to maintain a blood level of 10-20 ng/mL. 
For the patients with grade 2 or higher GVHD, intravenous 
methylprednisolone (2 mg/kg/day) was administered.
We categorized the patients into 2 groups according to 
the severity of acute GVHD: patients presenting with grade 
2 acute GVHD (N=9) and patients with grade 3-4 acute 
GVHD (N=6). 
2. Serum BAFF and APRIL
Patients’ clinical characteristics and the serum con-
centrations of BAFF and APRIL are summarized in Table 
2. The mean serum concentration of BAFF at diagnosis of 
acute GVHD was 1,524.85±1,181.34 pg/mL (mean±standard 
deviation). The median concentration of BAFF was 966.43 
pg/mL. The mean serum BAFF concentration of the control 
patients (4 patients without GVHD) was 1,107.84 pg/mL. 
The median absolute lymphocyte count (ALC) at diagnosis 
of acute GVHD was 0.92×10
9/L. The median serum 
concentration of BAFF to absolute lymphocyte count ratio 
(BAFF/ALC) was 1,073.81. The serum concentration of Korean J Hematol 2011;46:175-9.
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Table 3. Serum BAFF and APRIL levels according to grade of acute GVHD. 
Patients with grade 2 acute GVHD Patients with grade 3-4 acute GVHD P
N9 6
ALC (×10
9/L)    1.27±0.25   0.92±0.11 NS
Serum BAFF (pg/mL) 1,093.42±251.37 2,171.99±600.02 0.077
Serum BAFF/ALC    925.24±168.53 2,259.74±480.43 0.045
Serum APRIL (ng/mL)    1.82±0.67   2.65±0.53 0.077
Serum APRIL/ALC    2.29±1.30   2.82±0.40 0.013
Abbreviations: GVHD, graft-versus-host disease; ALC, Absolute lymphocyte count; BAFF, B cell-activating factor; APRIL, a proliferation-inducing
ligand; NS, not significant.
APRIL at diagnosis of acute GVHD was 2.15±1.76 ng/mL 
(median, 1.36 ng/mL). The mean serum APRIL concentration 
of the control patients was 0.98 ng/mL. The median serum 
concentration of APRIL to absolute lymphocyte count ratio 
(APRIL/ALC) was 1.42. 
The patients who had higher BAFF levels showed a trend 
of elevated APRIL levels, although the difference was not 
significant (P=0.060, Spearman’s correlation test). However, 
the value of BAFF/ALC showed a significant correlation with 
the value of APRIL/ALC (P=0.024, Spearman’s correlation 
test). There was no significant correlation between BAFF/ 
ALC or APRIL/ALC level and onset date of acute GVHD 
(P=0.859, 0.086, respectively). 
The BAFF/ALC or APRIL/ALC ratios at the diagnosis of 
acute GVHD had no correlation with the degree of response 
to high-dose steroid therapy for acute GVHD or the risk 
of relapse after the initial high dose of steroids.
3. Relationship between serum BAFF and APRIL levels and 
grade of acute GVHD
When we divided the enrolled patients into 2 groups 
according to the severity of acute GVHD, 9 patients had 
grade 2 acute GVHD and 6 patients suffered from grade 
3-4 acute GVHD (Table 3). The serum concentration of BAFF 
was higher in the patients with grade 3-4 acute GVHD 
(2,171.99±600.02 pg/mL) than in the patients with grade 
2 acute GVHD (1,093.42±251.37 pg/mL), although the 
difference was not significant (P=0.077). However, the 
patients with grade 3-4 acute GVHD showed a significantly 
higher BAFF/ALC ratio (2,259.74±480.43) than the patients 
with grade 2 acute GVHD (925.24±168.53, P=0.045). The 
patients with grade 3-4 acute GVHD also had a trend for 
higher serum concentrations of APRIL (P=0.077) and a 
significantly higher APRIL/ALC ratio (2.29±1.30 in grade 
2 vs. 2.82±0.40 in grade 3-4, P=0.013) (Table 3).
DISCUSSION
This study showed that BAFF/ALC or APRIL/ALC values 
at diagnosis of acute GVHD are associated with the severity 
of the condition. Therefore, B cells might play an important 
role in development and progression of acute GVHD. As 
a result, the BAFF/ALC or APRIL/ALC ratio at diagnosis 
o f  a c u t e  G V H D  m i g h t  b e  u s e d  a s  a  p r e d i c t i v e  f a c t o r  t o  
estimate its final severity.
Although the role of B cells in the development of chronic 
GVHD is relatively well known, their role in the develop-
ment of acute GVHD is still controversial. Furthermore, 
it is very difficult to evaluate the role of B cells from the 
donor or recipient in the development of acute GVHD, 
because the reconstitution of the B cell compartment 
required for humoral immunity may take up to 2 years after 
HSCT [13]. There is some evidence for adverse effects of 
donor B cells. High numbers of B cells in apheresis products 
correlated with an increased incidence of acute GVHD and 
increased treatment-related mortality [14]. Early-phase 
clinical trials indicate that B cell depletion with rituximab 
has beneficial effects on acute GVHD [3]. We showed that 
a higher serum concentration of B cell-activating factors 
such as BAFF or APRIL at diagnosis of acute GVHD might 
be associated with a higher grade of acute GVHD. Therefore, 
we concluded that B cells might play an important role 
in the development of acute GVHD, and BAFF/ALC or 
APRIL/ALC might be significant predictive factors for 
estimating the severity of the condition.
A higher grade of acute GVHD is often accompanied by 
unresponsiveness to high-dose steroid therapy and, fre-
quently, a fatal outcome. Many researchers have looked for 
new biomarkers to diagnose and predict the severity of acute 
GVHD. Such a test could help physicians decide more 
quickly, which patients need urgent treatment. The diagnosis 
of acute GVHD is still performed solely by close examination 
of skin lesions or monitoring of clinical signs such as diarrhea, 
and it is very difficult to predict the final severity of acute 
GVHD at initial diagnosis using these methods. Several 
biomarkers associated with T cell activation such as soluble 
CD8, soluble IL-2 receptor, soluble CD40 ligand, and soluble 
CD28 have been evaluated for detecting higher grades of 
acute GVHD, before signs and symptoms emerge [11]. 
However, there have been no reports of biomarkers 
associated with B cell activation. Although our results suggest 
that a B cell-activating factor such as BAFF or APRIL might 
be an effective biomarker to predict the severity of acute 
GVHD, further study involving a larger number of patients 
should be performed to confirm the roles of these biomarkers 
in relation to B cell activation.
We evaluated the role of BAFF and APRIL at the onset Korean J Hematol 2011;46:175-9.
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of acute GVHD as predictive biomarkers for the development 
of acute GVHD. APRIL, like BAFF, is a molecule belonging 
to the TNF family, and is produced mainly by the same 
cells as BAFF [6, 7]. Because APRIL is a homologue of BAFF, 
and recent evidence has also identified it as an important 
survival factor in several human B-cell malignancies, such 
as chronic lymphocytic leukemia [15], we evaluated the 
predictive value of serum APRIL for acute GVHD in this 
study. Although a small number of reports have demonstrated 
a relationship between serum BAFF and acute GVHD [10], 
there have been no reports regarding changes of serum 
APRIL in patients with acute GVHD. According to our 
results, the value of APRIL/ALC showed a significant 
correlation with the value of BAFF/ALC (P=0.024, Spear-
man’s correlation test). Therefore, APRIL might also be of 
value in predicting the severity of acute GVHD, and 
activation of B cells may have a significant role in the 
development of acute GVHD. Considering these possibilities, 
anti-CD20 monoclonal antibody (rituximab) as well as a 
human monoclonal antibody against BAFF (belimumab) or 
APRIL might be beneficial in the treatment of acute GVHD. 
These findings should be analyzed in further studies with 
a larger patient population.
In this study, we evaluated the BAFF/ALC and APRIL/ALC 
ratios as well as BAFF and APRIL serum concentrations. 
Because the amount of BAFF per B cell is a critical 
determinant of autoreactive B cell survival, and the BAFF/B 
cell ratio is significantly higher in patients with chronic 
GVHD compared with healthy individuals [9], we additio-
nally analyzed BAFF and APRIL levels according to 
lymphocyte count in this study. Although absolute lym-
phocyte count does not exactly correlate with B cell count, 
we used the ALC in this study because it is easier to obtain 
in daily clinical practice. According to our results, BAFF/ALC 
or APRIL/ALC ratios might be better predictors of the 
severity of acute GVHD than BAFF or APRIL levels.
This study was the first report to analyze the relationship 
between the serum concentration of BAFF or APRIL at 
diagnosis of acute GVHD and the severity of the condition. 
Although BAFF and APRIL were not significant predictive 
markers in this study, our results suggest that they might 
still be important biomarkers for predicting the severity of 
acute GVHD.
In conclusion, we showed that patients with grade 3-4 
acute GVHD had BAFF/ALC and APRIL/ALC values that 
were significantly higher than those of patients with grade 
2 acute GVHD. B cell-related biomarkers such as BAFF or 
APRIL might be useful for evaluating acute GVHD severity, 
and B cell-targeted or BAFF/APRIL-targeted therapeutic 
approaches for the treatment of acute GVHD might give 
significant benefits. The clinical significance of this study 
should be further evaluated in a larger patient population.
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